Fisher Asset Management
BBIO icon

Fisher Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Fisher Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Sell
345,351
-6,277
-2% -$440K 0.01% 318
2026
Q1 		$26.1M Buy
351,628
+119,227
+51% +$8.64M 0.01% 301
2025
Q4 		$17.8M Buy
+232,401
New +$15.3M 0.01% 339
2022
Q1 		– Sell
-763,531
Closed -$12.7M – 960
2021
Q4 		$12.7M Buy
763,531
+194,266
+34% +$8.22M 0.01% 357
2021
Q3 		$26.7M Buy
+569,265
New +$30.5M 0.02% 286

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fisher Asset Management's BBIO Position: Q2 2026 in Review

Fisher Asset Management reduced its BridgeBio Pharma (BBIO) stake by 1.8% in Q2 2026, selling an estimated $440K and leaving 345,351 shares worth $25.7M. The position accounts for 0.01% of the portfolio, ranked #318.

Fisher Asset Management first reported a position in BBIO in Q3 2021 and has held it in 5 quarters since. The position peaked at $26.7M in Q3 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Fisher Asset Management held 345,351 shares of BridgeBio Pharma worth $25.7M as of Q2 2026.
  • Fisher Asset Management sold 6,277 BridgeBio Pharma shares in Q2 2026, an estimated $440K.
  • BridgeBio Pharma made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #318 holding.
  • Fisher Asset Management first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 5 quarters since.
  • Fisher Asset Management's BridgeBio Pharma position peaked at $26.7M in Q3 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.